drugset
drugset / Trial / NCT06602479

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

NCT06602479 ↗

Phase 2 Recruiting 488 enrolled AbbVie
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this Phase 2 study is to evaluate the safety and efficacy of SC MEDI0618 compared to placebo in participants with episodic migraine.

Timeline

Start
2024-10-07
Primary completion
2026-12-18
Completion
2027-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject MEDI0618 Monoclonal antibody — Subcutaneous

Indications

migraine disorder